Tags |
|
|
Links |
|
|
Digg It - Medical Billing - GP0 Record Fields 15 Through 21
Medical billing of parental nutrition claims is not an easy task. There are a lot of calculations that need to be done and a lot of things t
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
hat need to be accounted for such as the actual product being dispensed, calories per day and so on. Computer programs make the job a little
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
easier when billing through electronic media and NSF 3.01 specifications. In this installment we'll be covering the GP0 record, picking up
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
with field number 15.
GP0 field 15, position 63, is the ambulatory indicator. This field tells the carrier whether or not the patient is am
GP0 field 15, position 63, is the ambulatory indicator. This field tells the carrier whether or not the patient is am
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
bulatory. There are only two valid responses for this field. If the patient is ambulatory, an A is entered. If the patient is not ambulato
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ry, an N is entered. The field cannot be left blank or the claim will be denied.
GP0 field 16, position 64, is the other forms of nutrient
GP0 field 16, position 64, is the other forms of nutrient
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
indicator. This field tells the carrier if the patient is receiving other forms of nutrition other than what this CMN is prescribed for. Th
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
s is important because in some cases, if the patient is receiving other treatments, this claim may not be 100% payable. As it is, with Medic
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
are, most claims are only 80% anyway. But if other feedings are involved, this claim may be even less than 80% covered.
GP0 field 17, posit
GP0 field 17, posit
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ion 65, is the type of mix indicator. This field tells the carrier the type of mix being administered to the patient. There are basically o
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
nly two possible mixes. There is a home mix, where the ingredients are put together at the home or facility from various sources. This mix
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
is transmitted with the letter H. A premix is when the mix is something that already comes put together by the manufacturer and just needs t
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
o be administered out of the package. This mix is transmitted with the letter P.
GP0 field 18, positions 66 - 68, is the parental frequency
GP0 field 18, positions 66 - 68, is the parental frequency
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
field. This field tells the carrier how many times per week the patient is to be fed. If the frequency is less than 100 times per week, wh
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ch it will almost always be, the field must be left zero filled. So if the patient is fed three times a day, or 21 times in a seven day peri
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
od, the field is transmitted as 021.
GP0 field 19, positions 69 - 73, is the HCPCS procedure code. This field tells the carrier the procedu
GP0 field 19, positions 69 - 73, is the HCPCS procedure code. This field tells the carrier the procedu
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
re code associated with the item being fed to the patient. This is not like the procedure code in the F record, which tells the carrier the
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
condition of the patient or treatment of the patient.
GP0 fields 20 and 21, positions 74 - 77, are the two modifiers for the HCPCS procedure
GP0 fields 20 and 21, positions 74 - 77, are the two modifiers for the HCPCS procedure
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
code. These fields transmit these modifiers to the carrier. The modifiers are usually determined by the month number of the CMN itself.
I
I
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
n our next installment of medical billing of claims via electronic media, we'll pick up our discussion of the GP0 record with field number 22
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/2269/diggit-Medical-Billing--GP0-Record-Fields-15-Through-21.html">Medical Billing - GP0 Record Fields 15 Through 21</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/2269/diggit-Medical-Billing--GP0-Record-Fields-15-Through-21.html]Medical Billing - GP0 Record Fields 15 Through 21[/url]
Related Articles:
Bookmark it:
|